Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin

Asian Pacific Journal of Cancer Prevention

Volumn 9, Issue 4, 2008, Pages 683-686

  Kaya, Ali Osman ^a   Coskun, Ugur ^a   Unlu, Mustafa ^a   Akdemir, Umit Ozgur ^a   Ozdemir, Nuriye Yildirim ^a   Zengin, Nurullah ^a   Benekli, Mustafa ^a   Yildiz, Ramazan ^a   Yaman, Emel ^a   Ozturk, Banu ^a   Gumus, Mahmut ^a   Uner, Aytug ^a   Yamac, Deniz ^a   Ucgul, Emel ^a   Buyukberber, Suleyman ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

18F FDG PET CT; Carcinoma of unknown primary; CUP; Survival

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER INVASION; CANCER OF UNKNOWN PRIMARY SITE; CANCER STAGING; CAUSE OF DEATH; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG TUMOR; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; NONPARAMETRIC TEST; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STOMACH TUMOR; SURVIVAL; WHOLE BODY IMAGING;

ADENOCARCINOMA; ADULT; AGED; BREAST NEOPLASMS; CAUSE OF DEATH; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS, UNKNOWN PRIMARY; POSITRON-EMISSION TOMOGRAPHY; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 66149101699     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Abbruzzese J, Abbruzzese M, Lenzi R et al (1995). Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol, 13, 2094-110.
2. Alberini JL, Belhocine T, Hustinx R, et al (2003). Whole body positron emission tomography using fluorodeoxyglucose in patients with with metastases of unknown primary tumours (CUP syndrome). Nucl Med Commun, 24, 1081-6.
3. Bohuslavizki KH, Klutmann S, Kroger S et al (2000). FDG PET detection of unknown primary tumors. J Nucl Med, 41, 816-22.
4. Fencl P, Belohlavek O, Skopalova M, et al (2007). Prognostic and diagnostic accuracy of 18 F-FDG-PET/CT in patients with carcinoma of unknown primary. Eur J Nucl Med Mol Imaging [Epub ahead of print].
5. Gutzeit A, Antoch G, Kuhl H et al (2005). Unknown primary tumors: detection with dual-modality PET/CT: initial experience. Radiology, 234, 227-34.
6. Hany TF, Steinert HC, Goerres GW, et al (2002). PET diagnostic accuracy: improvement with in-line PET CT system: initial results. Radiology, 225, 575-81.
7. Hess KR, Abbruzzese MC, Lenzi R, et al (1999). Classification and regression tree analysis of 1000 consecutive patients with unknown primaty carcinoma. Clin Cancer Res, 5, 3403-10.
8. Kole AC, Nieweg OE, Pruim j et al (1998). Detection of unknown occult primary tumors using positron emission tomography. Cancer, 82, 1160-6.
9. Le Chevalier T, Cvitkovic E, Caille P et al (1988). Early metastatic cancer of unknown primary origin at presentation. Arch Intern Med, 148, 2035-9.
10. Lenzi R, Hess KR, Abbruzzese MC, et al (1997). Poorly differentiated carcinoma and poorly differrentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma? J Clin Oncol, 15, 2056-66.
11. Levi F, Te VC, Erler G, et al (2002). Epidemiology of unknown primary tumours. Eur J Cancer, 38, 1810-2.
12. Maiche AG (1993). Cancer of unknown primary. A retrospective study based on 109 patients. Am J Clin Oncol, 16, 26-9.
13. Nanni C, Rubello D, Castellucci P et al (2005). Role of 18F-FDG PET-CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients. Eur J Nucl Med Mol Imaging, 32, 589-92.
14. Naresh KN (2002). Do metastatic tumours from an unknown primary reflect angiogenic incompetence of the tumour at the primary site? A hypothesis. Med Hypotheses, 59, 357-60.
15. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA (2003). Diagnostic and therapeutic management of cancer of unknown primary. Eur J Cancer, 39, 1990-2005.
16. Pelosi E, Messa C, Sironi S et al (2004). Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Imaging, 31, 932-9.
17. Pelosi E, Pennone M, Deandreis D, et al (2006). Role of whole body positron emission tomography/computed tompgraphy scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Q J Nucl Med Mol Imaging, 50, 15-22.
18. Raber MN, Faintuch J, Abbruzzese JL et al (1991). Continuous infusion 5-fluorouracil, etoposide and cisplatin in patients with metastatic carcinoma of unknown primary origin. Ann Oncol, 2, 519-20.
19. Steckel RJ, Kagan AR (1980). Diagnostic persistence in working up metastatic cancer with an unknown primary site. Radiology, 134, 367-9.
20. van de Wouw AJ, Janssen-Heijnen ML, Coeberg JW, Hillen HF (2002). Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer, 38, 409-13.